About this page
Insider trades reported on SEC Form 4: when the people who run a company buy or sell its shares with their own money.
How to read it
- Form 4
- The form a company insider (officer, director or owner of more than 10%) must file with the SEC within two business days of buying or selling the company's shares.
- Buy (P) and Sell (S)
- Open-market purchases and sales. Gifts, option exercises and automatic tax withholding are left out because they say little about what the insider thinks.
- Value
- Shares times price, as reported on the filing.
- 10b5-1
- A trade made under a plan set up in advance. Planned sales are common and usually say less than an unplanned purchase.
- Late filing
- A Form 4 filed more than two business days after the trade.
- Vs. S&P 500
- How the stock did after the trade minus how the overall market did in the same weeks.
A real example
In January 2016, when bank stocks were falling, JPMorgan Chase CEO Jamie Dimon bought 500,000 JPMorgan shares with his own money, worth about $26 million. His Form 4 made the purchase public within days, and investors read it as a strong sign of confidence.
Explain it like I'm 13
If the coach of a team bets his own allowance that his team will win, that tells you something. A Form 4 is the note a company boss must hand in whenever he buys or sells his own company's shares, so everyone can see it.
Data from public SEC filings and congressional reports. Information, not investment advice. Check every number against the filing linked on the page.
VERACYTE, INC. (VCYT): Insider Trades and Fund Holdings
In the past 12 months, VERACYTE, INC. insiders reported no open-market purchases and 7 sales worth $1.39M; 7 of the sales were reported as made under a 10b5-1 trading plan.
Timeline: news and trades
Company filings (8-K), insider trades, notices of planned sales (Form 144) and fund moves in the past year, newest first.
- Oct 27, 2026Planned saleKARIN EASTHAM (director) filed notice to sell about $715,770 around Oct 27, 2026
- Oct 27, 2026Planned saleJENS HOLSTEIN (director) filed notice to sell about $375,000 around Oct 27, 2026
- Oct 19, 2026Insider saleDirector Muna Bhanji sold $81,457 under a 10b5-1 plan
- Sep 24, 2026Planned saleJENS HOLSTEIN (director) filed notice to sell about $352,500 around Sep 24, 2026
- Sep 21, 2026Insider saleGlobal Chief Commercial Off John Leite sold $160,600 under a 10b5-1 plan (7 days after: signed a material agreement)
- Sep 21, 2026Planned saleJOHN LEITE (officer) filed notice to sell about $159,777 around Sep 21, 2026
- Sep 14, 2026NewsCompany reported: Signed a material agreement; Completed an acquisition or sale of assets
- Sep 14, 2026Insider saleDirector Jens Holstein sold $204,747 under a 10b5-1 plan (0 days after: signed a material agreement)
- Sep 14, 2026Planned saleJENS HOLSTEIN (director) filed notice to sell about $204,747 around Sep 14, 2026
- Sep 4, 2026Insider saleChief Scientific & Med Officer Phillip G. Febbo sold $564,410 under a 10b5-1 plan
- Sep 4, 2026Insider saleCFO Rebecca Chambers sold $157,394 under a 10b5-1 plan
- Sep 4, 2026Insider saleGeneral Counsel Annie McGuire sold $140,212 under a 10b5-1 plan
- Sep 4, 2026Planned salePHILLIP FEBBO (officer) filed notice to sell about $585,624 around Sep 4, 2026
- Sep 4, 2026Planned saleREBECCA CHAMBERS (officer) filed notice to sell about $163,135 around Sep 4, 2026
- Sep 4, 2026Planned saleANN MCGUIRE (officer) filed notice to sell about $145,356 around Sep 4, 2026
- Sep 1, 2026Insider saleDirector Muna Bhanji sold $80,096 under a 10b5-1 plan
- Sep 1, 2026Planned saleMUNA BHANJI (director) filed notice to sell about $161,012 around Sep 1, 2026
- Jun 30, 2026FundBridgewater Associates cut 36% in Q2 2026 (13F filed Aug 14, 2026)
- Jun 30, 2026FundRenaissance Technologies sold out in Q2 2026 (13F filed Aug 13, 2026)
Recent insider trades
Open-market purchases (code P) and sales (code S) from Form 4. Grants, option exercises and gifts are not shown. Latest filing: Oct 20, 2026.
| Filed | Insider | Type | Value |
|---|---|---|---|
| Oct 20 | Muna BhanjiDirector | ▼ SELL10b5-1 | $81K |
| Sep 22 | John LeiteGlobal Chief Commercial Off | ▼ SELL10b5-1 | $161K |
| Sep 16 | Jens HolsteinDirector | ▼ SELL10b5-1 | $205K |
| Sep 4 | Phillip G. FebboChief Scientific & Med Officer | ▼ SELL10b5-1 | $564K |
| Sep 4 | Rebecca ChambersCFO | ▼ SELL10b5-1 | $157K |
| Sep 4 | Annie McGuireGeneral Counsel | ▼ SELL10b5-1 | $140K |
| Sep 3 | Muna BhanjiDirector | ▼ SELL10b5-1 | $80K |
Insiders who traded in the past year
| Insider | Role | Buys | Bought | Sells | Sold |
|---|---|---|---|---|---|
| Muna Bhanji | Director | 0 | $0 | 2 | $162K |
| John Leite | Global Chief Commercial Off | 0 | $0 | 1 | $161K |
| Jens Holstein | Director | 0 | $0 | 1 | $205K |
| Phillip G. Febbo | Chief Scientific & Med Officer | 0 | $0 | 1 | $564K |
| Rebecca Chambers | CFO | 0 | $0 | 1 | $157K |
| Annie McGuire | General Counsel | 0 | $0 | 1 | $140K |
Buybacks and executive pay
| Year | CEO pay reported | CEO pay "actually paid" | Value of $100 invested |
|---|---|---|---|
| 2025 | $7.42M | $9.61M | n/a |
From the company's XBRL data filed with the SEC. "Actually paid" is the SEC's pay-versus-performance measure, which counts changes in the value of stock awards. "Value of $100 invested" is the company's cumulative shareholder return as reported, usually measured from five years earlier. See all buybacks and CEO pay across companies.
A All 7 insider trades reported on time. How it is graded
Tracked funds that report VCYT
From each fund's latest 13F. Holdings are as of quarter end and are filed up to 45 days later.
| Fund | Shares | Value | Change |
|---|---|---|---|
| Bridgewater Associates | 58,289 | $3.42M | ▼ −36.4% |
| Renaissance Technologies | 0 | $0 | ▼ Sold out |
Reading these numbers
Insiders sell for many reasons: taxes, diversification, a house. Purchases with their own money are rarer and are usually read as more informative. A Form 4 is due within two business days of the trade. How to read a Form 4 →